FCF Yield

Catalyst Pharmaceuticals' free cash flow (FCF) yield of 5.4% means that for every dollar you invest in the stock, the company generates about 5.4 cents in free cash flow annually — a measure of cash profits after operating and capital expenses.

That yield is above the healthcare sector median of 3.3%, placing the stock in the 81st percentile among sector peers, indicating stronger cash generation relative to many competitors. The trend direction is not available because historical values are limited to a single data point, with both year-over-year and quarter-over-quarter changes marked as N/A. The combination of a high FCF yield with no trend data creates a mixed picture: the level suggests the stock offers above-average cash returns, but the absence of trend information prevents assessing whether that yield is improving or deteriorating. This metric supports the overall NEUTRAL verdict, as the positive relative yield is a favorable signal, but without trend context it is insufficient to shift the rating to bullish or bearish.

Frequently Asked Questions

Closest Sector Peers